Home / Doctor Speaks  / APPLICATIONS OF 311 NM NARROW BAND UVB THERAPY IN THE TREATMENT OF VITILIGO

APPLICATIONS OF 311 NM NARROW BAND UVB THERAPY IN THE TREATMENT OF VITILIGO

Munir Ahmad., Zh.M.Umarov, F.Kh. Abboskhonova. Tashkent medical academy Dermatovenereology and Cosmetology Department   Objective: To compare the efficacy of low-dose immunosuppressive combination therapy with UVB-311nm versus UVB-311nm alone for the treatment of patients with vitiligo. Materials and methods: 41 patients

Munir Ahmad., Zh.M.Umarov, F.Kh. Abboskhonova.

Tashkent medical academy

Dermatovenereology and Cosmetology Department

 

Objective: To compare the efficacy of low-dose immunosuppressive combination therapy with UVB-311nm versus UVB-311nm alone for the treatment of patients with vitiligo.

Materials and methods: 41 patients with vitiligo were divided into 2 groups: group 1 (27 people) received combination therapy with an immunosuppressor 25 mg once a day in combination with UVB 311-nm phototherapy, group 2 (14 people) received UVB-311 monotherapy nm. Patients were followed up for 1 month. Evaluation of the effectiveness of therapy was carried out on the basis of the VASI index (vitiligo prevalence and severity index).

Results: perifollicular repigmentation started on average after 3 sessions of UVB-311 nm in group 1 and 6 sessions in group 2. During the control of blood parameters in group 1, no deviations from the reference values ​​were observed. There were no significant side effects from therapy in both groups. After 2 months of therapy, pronounced repigmentation of lesions in group 1 was observed in 10 (47.8%) patients, in group 2 in 4 (20.7%) patients. When analyzing the results of therapy, the VASI index decreased by an average of 70% in patients of group 1, in group 2 – by 30%.

Conclusions: An immunosuppressant may potentiate repigmentation in combination with UVB-311nm in patients with non-segmental vitiligo. The use of this combination therapy is a promising treatment for vitiligo, but further studies are required with the inclusion of a larger sample of patients.

medgatetoday@gmail.com

Review overview
NO COMMENTS

POST A COMMENT